CD8A and neoplasm: Collectively, we hypothesized that silencing BCAP31 in TAM could inactivate the JAK2-STAT3 signaling pathway in tumor cells, and leading to enhanced levels of pro-immune cytokines, consequently, activated CD8+ T cells.